Macrocyclic proline derived hcv serine protease inhibitors

摘要

The present disclosure relates to compounds of Formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof: Formula (I) which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present disclosure interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present disclosure further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The disclosure also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present disclosure.